Cryoport, Inc. (NASDAQ:CYRX) Given Average Rating of “Moderate Buy” by Brokerages

Cryoport, Inc. (NASDAQ:CYRX) has received an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $12.29.

CYRX has been the subject of a number of research reports. Roth Mkm lowered their target price on Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, November 8th. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Cryoport in a research note on Friday, January 17th. Guggenheim started coverage on shares of Cryoport in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 price objective for the company. Finally, UBS Group increased their price objective on shares of Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a research note on Friday, October 18th.

Cryoport Price Performance

CYRX stock opened at $8.04 on Wednesday. The stock has a 50-day moving average price of $7.78 and a two-hundred day moving average price of $7.96. The stock has a market cap of $397.42 million, a PE ratio of -2.38 and a beta of 1.58. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. Cryoport has a 1 year low of $5.32 and a 1 year high of $20.10.

Cryoport (NASDAQ:CYRX) last released its earnings results on Thursday, November 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.23. The firm had revenue of $56.66 million during the quarter, compared to analysts’ expectations of $58.13 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same quarter in the prior year, the company earned ($0.31) EPS. Equities analysts forecast that Cryoport will post -0.99 EPS for the current fiscal year.

Insider Activity at Cryoport

In related news, Director Ramkumar Mandalam sold 7,369 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $7.46, for a total value of $54,972.74. Following the completion of the sale, the director now directly owns 59,497 shares in the company, valued at approximately $443,847.62. This trade represents a 11.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Jerrell Shelton sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $6.78, for a total transaction of $339,000.00. Following the completion of the sale, the chief executive officer now owns 712,747 shares of the company’s stock, valued at $4,832,424.66. This trade represents a 6.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 109,869 shares of company stock worth $735,673. Insiders own 10.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CYRX. Rhumbline Advisers raised its holdings in Cryoport by 3.4% in the 2nd quarter. Rhumbline Advisers now owns 64,158 shares of the company’s stock valued at $443,000 after acquiring an additional 2,086 shares during the period. Hsbc Holdings PLC bought a new position in Cryoport in the 2nd quarter valued at about $92,000. XTX Topco Ltd bought a new position in Cryoport in the 2nd quarter valued at about $198,000. Marshall Wace LLP bought a new position in Cryoport in the 2nd quarter valued at about $282,000. Finally, Cubist Systematic Strategies LLC bought a new position in Cryoport in the 2nd quarter valued at about $378,000. 92.90% of the stock is owned by institutional investors.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.